Brain Atrophy Does Not Predict Clinical Progression in Progressive Supranuclear Palsy

Baseline clinical severity and brain atrophy could not predict individual clinical progression, suggesting no need for MRI-based stratification of patients in future PSP trials. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Authors

Institutions

Publication Details

Journal
Movement Disorders
Published
2025-08-30
DOI
https://doi.org/10.1002/mds.70026
Citations
3
Primary Topic
Parkinson's Disease Mechanisms and Treatments
Type
article
Field-Weighted Citation Impact
4.17

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Brain Atrophy Does Not Predict Clinical Progression in Progressive Supranuclear Palsy

Emrah Düzel, Nicholas Seneca, Andrea Quattrone, Hans‐Jürgen Huppertz et al.
3 citations
Movement Disorders
Parkinson's Disease Mechanisms and Treatments
4.17
article

Brain Atrophy Does Not Predict Clinical Progression in Progressive Supranuclear Palsy

Emrah Düzel, Nicholas Seneca, Andrea Quattrone, Hans‐Jürgen Huppertz, Annika Spottke, Gabor C. Petzold, Johannes Levin, Günter U. Höglinger, Johannes Prudlo, Nicolai Franzmeier
article en
3 citations

Abstract

Baseline clinical severity and brain atrophy could not predict individual clinical progression, suggesting no need for MRI-based stratification of patients in future PSP trials. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Movement DisordersVol. 40(11)
University of Bonn (DE), University Hospital Bonn (DE), German Center for Neurodegenerative Diseases (DE), AbbVie (United States) (US), LMU Klinikum (DE), Magna Graecia University (IT), Munich Cluster for Systems Neurology (DE), Swiss Epilepsy Center (CH), University College London (GB), University of Rostock (DE), Ludwig-Maximilians-Universität München (DE), University of Gothenburg (SE), Otto-von-Guericke-Universität Magdeburg (DE)
Bristol-Myers Squibb, Pfizer, Sanofi, Biogen, Teva Pharmaceutical Industries, University of Pennsylvania, Universidade de Aveiro, Johns Hopkins University, Pennsylvania State University, University of Ottawa, Rush University, Deutsches Krebsforschungszentrum, Korea University Guro Hospital, Ochsner Health, Imperial College London, University College London, Deutsche Forschungsgemeinschaft, Volkswagen Foundation, Eberhard Karls Universität Tübingen, Korea University, Technische Universität Dresden, Forschungszentrum Jülich, Ministero della Salute, University of Toronto, Eisai, Universidad de Navarra, Deutsches Zentrum für Neurodegenerative Erkrankungen, Technische Universität München, Ludwig-Maximilians-Universität München, Humboldt-Universität zu Berlin, Freie Universität Berlin, Universität zu Köln, Rheinische Friedrich-Wilhelms-Universität Bonn, Universität Ulm, Centre Hospitalier Universitaire de Bordeaux, Servier, Deutschen Konsortium für Translationale Krebsforschung, Universitätsklinikum Köln, Universität Rostock, H. Lundbeck A/S, Institute for Translational Neuroscience, Bayer Vital, Leibniz-Gemeinschaft, School of Public Health, Imperial College London, NIH Clinical Center
Openalex Percentile: Top 5%
Parkinson's Disease Mechanisms and Treatments
4.17
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.